Article thumbnail

Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway

By Youssef H. Zeidan, Russell W. Jenkins and Yusuf A. Hannun


The chemotherapeutic agent cisplatin is widely used in treatment of solid tumors. In breast cancer cells, cisplatin produces early and marked changes in cell morphology and the actin cytoskeleton. These changes manifest as loss of lamellipodia/filopodia and appearance of membrane ruffles. Furthermore, cisplatin induces dephosphorylation of the actin-binding protein ezrin, and its relocation from membrane protrusions to the cytosol. Because cisplatin activates acid sphingomyelinase (ASMase), we investigate here the role of the ASMase/ceramide (Cer) pathway in mediating these morphological changes. We find that cisplatin induces a transient elevation in ASMase activity and its redistribution to the plasma membrane. This translocation is blocked upon overexpression of a dominant-negative (DN) ASMaseS508A mutant and by a DN PKCδ. Importantly; knockdown of ASMase protects MCF-7 cells from cisplatin-induced cytoskeletal changes including ezrin dephosphorylation. Reciprocally, exogenous delivery of D-e-C16-Cer, but not dihydro-C16-Cer, recapitulates the morphotropic effects of cisplatin. Collectively, these results highlight a novel tumor suppressor property for Cer and a function for ASMase in cisplatin-induced cytoskeletal remodeling

Topics: Research Articles
Publisher: The Rockefeller University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor- { alpha } -induced PGE2 production.
  2. (2007). Activation of acid sphingomyelinase by protein kinase
  3. (2004). Cathepsin D links TNF-induced acid sphingo-JCB
  4. (1999). Cathepsin D targeted by acid sphingomyelinase-derived ceramide.
  5. (2000). Ceramide as an activator lipid of cathepsin D.
  6. (2003). Chemokine stimulation of human peripheral blood T lymphocytes induces rapid dephosphorylation of ERM proteins, which facilitates loss of microvilli and polarization.
  7. (2004). Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension.
  8. (2002). ERM proteins and merlin: integrators at the cell cortex.
  9. (2007). ERM proteins in epithelial cell organization and functions.
  10. (2004). Ezrin … a metastatic detERMinant?
  11. (2001). FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1.
  12. (2003). Implication of raft microdomains in drug induced apoptosis.
  13. (2005). Involvement of cathepsin D in chemotherapyinduced cytochrome c release, caspase activation, and cell death.
  14. (1997). Lipid composition and phospholipid asymmetry of membranes from a Schwann cell line.
  15. (1999). Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecifi c and regulated by phosphatidic acid.
  16. (1998). Mammalian cell mutants resistant to a sphingomyelin-directed cytolysin. Genetic and biochemical evidence for complex formation of the LCB1 protein with the LCB2 protein for serine palmitoyltransferase.
  17. (2000). Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane.
  18. (2002). Ordering ceramide-induced cell detachment and apoptosis in human neuroepithelioma.
  19. (2004). Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin.
  20. (2006). Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry.
  21. (2002). Spatiotemporal regulation of moesin phosphorylation and rear release by Rho and serine/threonine phosphatase during neutrophil migration. Exp. Cell Res.
  22. (2006). Sphingosine 1-phosphate regulates cytoskeleton dynamics: implications in its biological response.
  23. (2006). Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains.
  24. (2004). The structural requirements for ceramide activation of serine-threonine protein phosphatases.
  25. (1997). Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity.
  26. (2005). UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal.